Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 27, 2015

Vismodegib Safe and Effective in Advanced Basal Cell Carcinoma

Journal of the American Academy of Dermatology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
Pivotal ERIVANCE Basal Cell Carcinoma (BCC) Study: 12-Month Update of Efficacy and Safety of Vismodegib in Advanced BCC
J Am Acad Dermatol 2015 Jun 01;72(6)1021-1026.e8, A Sekulic, MR Migden, K Lewis, JD Hainsworth, JA Solomon, S Yoo, ST Arron, PA Friedlander, E Marmur, CM Rudin, AL Chang, L Dirix, J Hou, H Yue, A Hauschild

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading